Dublin, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The "Infusion Pumps and Devices: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. This report aims to provide a ...

US & Canada, Jan. 24, 2025 (GLOBE NEWSWIRE) -- According to a comprehensive report from The Insight Partners, “Infusion Devices Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for SPN-830, an apomorphine infusion device for the continuous treatment of motor fluctuations ...

New devices address infusion delivery variability and expand the ICU Medical IV Performance Platform. Unlike traditional pumps that rely on specific setups and conditions for accurate delivery, ...

Swiss diabetes device maker CeQur roped in $100 million in a Series C round for its patchlike insulin infusion device, helping the company ramp up operations and launch its product next year. Woodford ...

A Prescription Drug User Fee Act target date of February 1, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application (NDA) ...

LONDON--(BUSINESS WIRE)--The global infusion therapy devices market is expected to post a CAGR of 6% during the period 2019-2023, according to the latest market research report by Technavio.

Questions about an infusion device have scuttled Supernus Pharmaceuticals’ attempt to win approval of a Parkinson’s disease therapy. The complete response letter marks the second time in two years ...

DUBLIN--(BUSINESS WIRE)--The "Global Infusion Therapy Devices Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The infusion therapy devices market will register a CAGR of ...

LONDON (Reuters) - Privately held company CeQur, which is developing the world’s first three-day insulin infusion device for people with type 2 diabetes, has raised $100 million in a funding round ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...